Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV–MCD) and the KSHV Inflammatory Cytokine Syndrome
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Soon after the discovery of Kaposi sarcoma (KS)-associated herpesvirus (KSHV), it was appreciated that this virus was associated with most cases of multicentric Castleman disease (MCD) arising in patients infected with human immunodeficiency virus. It has subsequently been recognized that KSHV-MCD is a distinct entity from other forms of MCD. Like MCD that is unrelated to KSHV, the clinical presentation of KSHV-MCD is dominated by systemic inflammatory symptoms including fevers, cachexia, and laboratory abnormalities including cytopenias, hypoalbuminemia, hyponatremia, and elevated C-reactive protein. Pathologically KSHV-MCD is characterized by polyclonal, IgM-lambda restricted plasmacytoid cells in the intrafollicular areas of affected lymph nodes. A portion of these cells are infected with KSHV and a sizable subset of these cells express KSHV lytic genes including a viral homolog of interleukin-6 (vIL-6). Patients with KSHV-MCD generally have elevated KSHV viral loads in their peripheral blood. Production of vIL-6 and induction of human (h) IL-6 both contribute to symptoms, perhaps in combination with overproduction of IL-10 and other cytokines. Until recently, the prognosis of patients with KSHV-MCD was poor. Recent therapeutic advances targeting KSHV-infected B cells with the anti-CD20 monoclonal antibody rituximab and utilizing KSHV enzymes to target KSHV-infected cells have substantially improved patient outcomes. Recently another KSHV-associated condition, the KSHV inflammatory cytokine syndrome (KICS) has been described. Its clinical manifestations resemble those of KSHV-MCD but lymphadenopathy is not prominent and the pathologic nodal changes of KSHV-MCD are absent. Patients with KICS exhibit elevated KSHV viral loads and elevation of vIL-6, homolog of human interleukin-6 and IL-10 comparable to those seen in KSHV-MCD; the cellular origin of these is a matter of investigation. KICS may contribute to the inflammatory symptoms seen in some patients with severe KS or primary effusion lymphoma. Additional research is needed to better define the clinical spectrum of KICS and its relationship to KSHV-MCD. In additional, research is needed to better understand the pathogenesis and epidemiology of both KICS and KSHV-MCD, as well as the optimal therapy for both of these disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's Sarcoma
Chang, Y., Cesarman, E., Pessin, M. S., Lee, F., Culpepper, J., Knowles, D. M., & Moore, P. S. (1994) · Science · doi:10.1126/science.7997879 · Cited by 5,654 · cited 1×
“…as the causative agent of a several human illnesses, including KS, primary effusion lymphoma (PEL), and, in the setting of human immunodeficiency virus (HIV) infection, almost all cases of multicentric Castleman disease (MCD; Chang et al., 1994; Cesarman et al., 1995; Soulier et al., 1995).”
BackgroundCesarman, E., Chang, Y., Moore, P. S., Said, J. W., & Knowles, D. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505043321802 · Cited by 2,818 · cited 2×
“REVIEW ARTICLE published: 02 March 2012 doi: 10.3389/fmicb.2012.00073 Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV–MCD) and the KSHV inflammatory cytokine syndrome”
BackgroundInfluentialSoulier, J., Grollet, L., Oksenhendler, E., Cacoub, P., Cazals-Hatem, D., Babinet, P., d'Agay, M., Clauvel, J., Raphael, M., Degos, L., et al. (1995) · Blood · doi:10.1182/blood.v86.4.1276.bloodjournal8641276 · Cited by 2,157 · cited 2×
“REVIEW ARTICLE published: 02 March 2012 doi: 10.3389/fmicb.2012.00073 Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV–MCD) and the KSHV inflammatory cytokine syndrome”
BackgroundInfluentialInterleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130 · cited 2×
“…to signal by forming a tetrameric complex with the IL-6 receptor superfamily gp130 component, which is widely expressed in human tissues, without requiring binding to the classical gp80 IL-6 receptor (Heinrich et al., 1998; Boulanger et al., 2004; Meads and Medveczky, 2004; Hu and Nicholas, 2006).”
BackgroundMolecular Mimicry of Human Cytokine and Cytokine Response Pathway Genes by KSHV
Moore, P. S., Boshoff, C., Weiss, R. A., & Chang, Y. (1996) · Science · doi:10.1126/science.274.5293.1739 · Cited by 904 · cited 3×
“Their sequence homology is approximately 25% (Moore et al., 1996; Neipel et al., 1997). vIL-6 has a signaling potency 100- to 1000-fold lower that that seen with hIL-6 in in vitro models (Aoki et al., 2000).”
BackgroundNorthfelt, D. W., Dezube, B. J., Thommes, J. A., Miller, B. J., Fischl, M. A., Friedman-Kien, A., Kaplan, L. D., Du Mond, C., Mamelok, R. D., & Henry, D. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2445 · Cited by 649 · cited 1×
“Liposomal doxorubicin has a high affinity for the pathogenic spindle cell in KS lesions, and, when available, is currently the standard of care for first line therapy of KS (Northfelt et al., 1998; Cianfrocca et al., 2010).”
BackgroundKinetics of Kaposi’s Sarcoma-Associated Herpesvirus Gene Expression
Sun, R., Lin, S.-F., Staskus, K., Gradoville, L., Grogan, E., Haase, A., & Miller, G. (1999) · Journal of Virology · doi:10.1128/jvi.73.3.2232-2242.1999 · Cited by 404 · cited 1×
“Like other herpesviruses, KSHV infection can exhibits both latent and lytic phases, distinguished by their viral gene expression patterns (Moore and Chang, 1998; Staskus et al., 1999; Sun et al., 1999).”
BackgroundKSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine
Ganem, D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40567 · Cited by 385 · cited 1×
“The KSHV genome is notable for its molecular piracy of cellular genes (Moore et al., 1996; Ganem, 2010).”
BackgroundDu, M.-Q. (2001) · Blood · doi:10.1182/blood.v97.7.2130 · Cited by 382 · cited 2×
“…of KSHV–MCD is made pathologically by a lymph node biopsy demonstrating hypocellular germinal centers with a vascularized core and by a proliferation of polyclonal, IgM λ-restricted plasmacytoid cells in the interfollicular area (Oksenhendler et al., 1996; Du et al., 2001; Chadburn et al., 2008).”
BackgroundKaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Gene Expression as Revealed by DNA Arrays
Jenner, R. G., Albà, M. M., Boshoff, C., & Kellam, P. (2001) · Journal of Virology · doi:10.1128/jvi.75.2.891-902.2001 · Cited by 379 · cited 2×
“5/vIRF2; a viral homolog of human interleukin-6 (hIL-6) called viral IL-6 (vIL-6; encoded by ORF K2); and a constitutively active G-protein coupled receptor (GPCR) with pro-angiogenic and immunomodulatory functions encoded by ORF74 (Aoki et al., 2000; Jenner et al., 2001; Yarchoan, 2006).”
BackgroundMulticentric Castlemanʼs disease in HIV infection: a clinical and pathological study of 20 patients
Oksenhendler, E., Duarte, M., Soulier, J., Cacoub, P., Welker, Y., Cadranel, J., Cazals-Hatem, D., Autran, B., Clauvel, J.-P., & Raphael, M. (1996) · AIDS · doi:10.1097/00002030-199601000-00009 · Cited by 358 · cited 5×
“…Center for Cancer Research, National Cancer Institute, National Institutes of Health, Room 6N106, Building 10, Bethesda, MD 20892-1868, USA. e-mail: robert.yarchoan@mail.nih.gov Soon after the discovery of Kaposi sarcoma (KS)-associated herpesvirus (KSHV), it was appreciated that this virus was…”
BackgroundInfluentialOksenhendler, E., Carcelain, G., Aoki, Y., Boulanger, E., Maillard, A., Clauvel, J.-P., & Agbalika, F. (2000) · Blood · doi:10.1182/blood.v96.6.2069 · Cited by 356
Castleman Disease: An Update on Classification and the Spectrum of Associated Lesions
Cronin, D. M. P., & Warnke, R. A. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181a9d4d3 · Cited by 311 · cited 2×
“There are several forms of Castleman disease, which historically have been distinguished by clinical findings (based on whether involved nodes are singular or multiple), pathologic findings, and more recently etiology (idiopathic or KSHV-associated; Cronin and Warnke, 2009).”
BackgroundUldrick, T. S., Wang, V., O’Mahony, D., Aleman, K., Wyvill, K. M., Marshall, V., Steinberg, S. M., Pittaluga, S., Maric, I., Whitby, D., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/654798 · Cited by 304
Self-citationHuman herpesvirus 8 encodes a homolog of interleukin-6
Neipel, F., Albrecht, J. C., Ensser, A., Huang, Y. Q., Li, J. J., Friedman-Kien, A. E., & Fleckenstein, B. (1997) · Journal of Virology · doi:10.1128/jvi.71.1.839-842.1997 · Cited by 292 · cited 2×
“Their sequence homology is approximately 25% (Moore et al., 1996; Neipel et al., 1997). vIL-6 has a signaling potency 100- to 1000-fold lower that that seen with hIL-6 in in vitro models (Aoki et al., 2000).”
BackgroundRegulation of NF-κB inhibitor IκBα and viral replication by a KSHV microRNA
Lei, X., Bai, Z., Ye, F., Xie, J., Kim, C.-G., Huang, Y., & Gao, S.-J. (2010) · Nature Cell Biology · doi:10.1038/ncb2019 · Cited by 264 · cited 1×
“There is evidence that these also interact with host proteins in ways that favor viral survival and may also induce expression of other host inflammatory proteins including IL-10 (Abend et al., 2010; Lei et al., 2010; Lu et al., 2010; Qin et al., 2010).”
BackgroundJones, K. D., Aoki, Y., Chang, Y., Moore, P. S., Yarchoan, R., & Tosato, G. (1999) · Blood · doi:10.1182/blood.v94.8.2871 · Cited by 250
Self-citationDysregulated interleukin 6 expression produces a syndrome resembling Castleman’s disease in mice
Brandt, S. J., Bodine, D. M., Dunbar, C. E., & Nienhuis, A. W. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114749 · Cited by 248 · cited 1×
“Viral and human IL-6 over-expression in mouse models can each produce phenotypes resembling that of KSHV–MCD (Brandt et al., 1990; Aoki et al., 2001b).”
BackgroundStaskus, K. A., Sun, R., Miller, G., Racz, P., Jaslowski, A., Metroka, C., Brett-Smith, H., & Haase, A. T. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.4181-4187.1999 · Cited by 242 · cited 4×
“By contrast, and unusually among herpesvirus-associated tumors, KSHV–MCD is associated with lytically active KSHV in a substantial proportion of KSHV-infected cells (Oksenhendler et al., 1996; Staskus et al., 1999; Parravicini et al., 2000).”
BackgroundInfluentialKaposi sarcoma-associated herpesvirus (KSHV): Molecular biology and oncogenesis
Wen, K. W., & Damania, B. (2010) · Cancer Letters · doi:10.1016/j.canlet.2009.07.004 · Cited by 231 · cited 2×
“, 2001), with expressed genes primarily being directed to enhance cell survival, inhibit apoptosis, and evade the host immune response (Moore and Chang, 1998; Wen and Damania, 2010).”
BackgroundViral IL-6-Induced Cell Proliferation and Immune Evasion of Interferon Activity
Chatterjee, M., Osborne, J., Bestetti, G., Chang, Y., & Moore, P. S. (2002) · Science · doi:10.1126/science.1074883 · Cited by 219 · cited 1×
“While vIL-6 is commonly referred to as a lytic gene, in some circumstances it may be expressed in the absence of full lytic activation (Chatterjee et al., 2002).”
BackgroundFifty years of multicentric Castleman's disease
Waterston, A., & Bower, M. (2004) · Acta Oncologica · doi:10.1080/02841860410002752 · Cited by 205 · cited 1×
“…surgical resection of the spleen, cytotoxic chemotherapy (either single agents or combinations), ganciclovir, glucocorticoids, and rituximab (Boulanger et al., 2004; Waterston and Bower, 2004; Dispenzieri and Gertz, 2005; Neuville et al., 2005; Bower et al., 2007; Mylona et al., 2008; Bower,2010).”
BackgroundBrief Communication: Rituximab in HIV-Associated Multicentric Castleman Disease
Bower, M., Powles, T., Williams, S., Davis, T. N., Atkins, M., Montoto, S., Orkin, C., Webb, A., Fisher, M., Nelson, M., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-12-200712180-00003 · Cited by 197
Monini, P., Colombini, S., Stürzl, M., Goletti, D., Cafaro, A., Sgadari, C., Buttò, S., Franco, M., Leone, P., Fais, S., et al. (1999) · PubMed · doi:10.1182/blood.v93.12.4044 · Cited by 189
Self-citationCianfrocca, M., Lee, S., Von Roenn, J., Tulpule, A., Dezube, B. J., Aboulafia, D. M., Ambinder, R. F., Lee, J. Y., Krown, S. E., & Sparano, J. A. (2010) · Cancer · doi:10.1002/cncr.25362 · Cited by 173 · cited 1×
“Liposomal doxorubicin has a high affinity for the pathogenic spindle cell in KS lesions, and, when available, is currently the standard of care for first line therapy of KS (Northfelt et al., 1998; Cianfrocca et al., 2010).”
BackgroundPowles, T., Stebbing, J., Bazeos, A., Hatzimichael, E., Mandalia, S., Nelson, M., Gazzard, B., & Bower, M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn697 · Cited by 170 · cited 1×
“By contrast to KS, there is evidence that MCD has become more common since the advent of combination anti-retroviral therapy (cART; Powles et al., 2009).”
Abend, J. R., Uldrick, T. S., & Ziegelbauer, J. M. (2010) · Journal of Virology · doi:10.1128/jvi.00884-10 · Cited by 164 · cited 5×
“There is evidence that these also interact with host proteins in ways that favor viral survival and may also induce expression of other host inflammatory proteins including IL-10 (Abend et al., 2010; Lei et al., 2010; Lu et al., 2010; Qin et al., 2010).”
BackgroundInfluentialSelf-citationRituximab therapy for HIV-associated Castleman disease
Marcelin, A., Aaron, L., Mateus, C., Gyan, E., Gorin, I., Viard, J., Cálvez, V., & Dupin, N. (2003) · Blood · doi:10.1182/blood-2003-03-0951 · Cited by 155 · cited 1×
“Several recent studies have reported that KSHV–MCD can respond to therapy with the anti-CD20 monoclonal antibody rituximab (Corbellino et al., 2001; Marcelin et al., 2003; Ocio et al., 2005; Bower et al., 2007).”
BackgroundUldrick, T. S., Polizzotto, M. N., Aleman, K., O'Mahony, D., Wyvill, K. M., Wang, V., Marshall, V., Pittaluga, S., Steinberg, S. M., Tosato, G., et al. (2011) · Blood · doi:10.1182/blood-2010-11-317610 · Cited by 152
Self-citationUmbach, J. L., & Cullen, B. R. (2009) · Journal of Virology · doi:10.1128/jvi.02013-09 · Cited by 146 · cited 1×
“KSHV also encodes at least 12 small non-coding microRNAs (miRNAs), whose functions are still to be comprehensively determined (Ganem and Ziegelbauer, 2008; Umbach and Cullen, 2010).”
BackgroundCorbellino, M., Bestetti, G., Scalamogna, C., Calattini, S., Galazzi, M., Meroni, L., Manganaro, D., Fasan, M., Moroni, M., Galli, M., et al. (2001) · Blood · doi:10.1182/blood.v98.12.3473 · Cited by 144 · cited 1×
“Several recent studies have reported that KSHV–MCD can respond to therapy with the anti-CD20 monoclonal antibody rituximab (Corbellino et al., 2001; Marcelin et al., 2003; Ocio et al., 2005; Bower et al., 2007).”
BackgroundQin, Z., Kearney, P., Plaisance‐Bonstaff, K., & Parsons, C. H. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0409251 · Cited by 143 · cited 2×
“REVIEW ARTICLE published: 02 March 2012 doi: 10.3389/fmicb.2012.00073 Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV–MCD) and the KSHV inflammatory cytokine syndrome”
BackgroundInfluentialToll-like receptor signaling controls reactivation of KSHV from latency
Gregory, S. M., West, J. A., Dillon, P., Hilscher, C., Dittmer, D. P., & Damania, B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905316106 · Cited by 141 · cited 2×
“role in maintaining viral persistence in the host (Gregory et al., 2009).”
BackgroundKSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways
Osborne, J., Moore, P. S., & Chang, Y. (1999) · Human Immunology · doi:10.1016/s0198-8859(99)00083-x · Cited by 135 · cited 2×
“REVIEW ARTICLE published: 02 March 2012 doi: 10.3389/fmicb.2012.00073 Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV–MCD) and the KSHV inflammatory cytokine syndrome”
BackgroundInfluentialHow I treat HIV-associated multicentric Castleman disease
Bower, M. (2010) · Blood · doi:10.1182/blood-2010-07-290213 · Cited by 132 · cited 1×
“…surgical resection of the spleen, cytotoxic chemotherapy (either single agents or combinations), ganciclovir, glucocorticoids, and rituximab (Boulanger et al., 2004; Waterston and Bower, 2004; Dispenzieri and Gertz, 2005; Neuville et al., 2005; Bower et al., 2007; Mylona et al., 2008; Bower,2010).”
BackgroundMicroRNAs encoded by Kaposi's sarcoma‐associated herpesvirus regulate viral life cycle
Lu, C., Li, Z., Chu, C., Feng, J., Feng, J., Sun, R., & Rana, T. M. (2010) · EMBO Reports · doi:10.1038/embor.2010.132 · Cited by 110 · cited 5×
“There is evidence that these also interact with host proteins in ways that favor viral survival and may also induce expression of other host inflammatory proteins including IL-10 (Abend et al., 2010; Lei et al., 2010; Lu et al., 2010; Qin et al., 2010).”
BackgroundInfluentialDetection of viral interleukin-6 in Kaposi sarcoma–associated herpesvirus–linked disorders
Aoki, Y., Yarchoan, R., Wyvill, K. M., Okamoto, S.-I., Little, R. F., & Tosato, G. (2001) · Blood · doi:10.1182/blood.v97.7.2173 · Cited by 107
Self-citationCannon, J. S., Hamzeh, F. M., Moore, S. M., Nicholas, J., & Ambinder, R. F. (1999) · Journal of Virology · doi:10.1128/jvi.73.6.4786-4793.1999 · Cited by 104 · cited 1×
“One KSHV lytic gene, ORF36, encodes a phosphotransferase that activates ganciclovir to a cytotoxic triphosphate moiety, and another, ORF21, encodes a thymidine kinase that phosphorylates zidovudine (AZT), again to a cytotoxic moiety (Cannon et al., 1999; Gustafson et al., 2000).”
BackgroundWu, W. W., Vieira, J., Fiore, N. C., Banerjee, P., Sieburg, M. A., Rochford, R. A., Harrington, W. A., & Feuer, G. (2006) · Blood · doi:10.1182/blood-2005-04-1697 · Cited by 101 · cited 3×
“KSHV can establish latency in various cell types including endothelial cells and B-lymphocytes (Monini et al., 1999; Wu et al., 2006; Della Bella et al., 2008).”
BackgroundTeruya‐Feldstein, J., Zauber, P., Setsuda, J., Berman, E. L., Sorbara, L. R., Raffeld, M. A., Tosato, G., & Jaffe, E. S. (1998) · PubMed · Cited by 96
Chadburn, A., Hyjek, E., Tam, W., Liu, Y.-F., Rengifo, T., Cesarman, E., & Knowles, D. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03144.x · Cited by 91 · cited 5×
“…of KSHV–MCD is made pathologically by a lymph node biopsy demonstrating hypocellular germinal centers with a vascularized core and by a proliferation of polyclonal, IgM λ-restricted plasmacytoid cells in the interfollicular area (Oksenhendler et al., 1996; Du et al., 2001; Chadburn et al., 2008).”
BackgroundInfluentialOcio, E., Sanchez-Guijo, F., Díez-Campelo, M., Castilla, C., Blanco, O., Caballero, D., & Miguel, J. S. S. (2005) · American journal of hematology/oncology · doi:10.1002/ajh.20283 · Cited by 88 · cited 1×
“Several recent studies have reported that KSHV–MCD can respond to therapy with the anti-CD20 monoclonal antibody rituximab (Corbellino et al., 2001; Marcelin et al., 2003; Ocio et al., 2005; Bower et al., 2007).”
BackgroundHIV‐associated multicentric Castleman's disease
Stebbing, J., Pantanowitz, L., Dayyani, F., Sullivan, R. J., Bower, M., & Dezube, B. J. (2008) · American Journal of Hematology · doi:10.1002/ajh.21137 · Cited by 87
Treatment of castleman’s disease
Dispenzieri, A. A., & Gertz, M. A. (2005) · Current Treatment Options in Oncology · doi:10.1007/s11864-005-0008-z · Cited by 87 · cited 1×
“…surgical resection of the spleen, cytotoxic chemotherapy (either single agents or combinations), ganciclovir, glucocorticoids, and rituximab (Boulanger et al., 2004; Waterston and Bower, 2004; Dispenzieri and Gertz, 2005; Neuville et al., 2005; Bower et al., 2007; Mylona et al., 2008; Bower,2010).”
BackgroundSerum viral interleukin-6 in AIDS-related multicentric Castleman disease
Aoki, Y., Tosato, G., Fonville, T. W., & Pittaluga, S. (2001) · Blood · doi:10.1182/blood.v97.8.2526 · Cited by 86 · cited 5×
“Viral and human IL-6 over-expression in mouse models can each produce phenotypes resembling that of KSHV–MCD (Brandt et al., 1990; Aoki et al., 2001b).”
BackgroundInfluentialGustafson, E., Schinazi, R. F., & Fingeroth, J. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.2.684-692.2000 · Cited by 85 · cited 1×
“One KSHV lytic gene, ORF36, encodes a phosphotransferase that activates ganciclovir to a cytotoxic triphosphate moiety, and another, ORF21, encodes a thymidine kinase that phosphorylates zidovudine (AZT), again to a cytotoxic moiety (Cannon et al., 1999; Gustafson et al., 2000).”
BackgroundKaposi's Sarcoma-Associated Herpesvirus-Encoded Oncogenes and Oncogenesis
Moore, P. S., & Chang, Y. (1998) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a024176 · Cited by 77 · cited 3×
“, 2001), with expressed genes primarily being directed to enhance cell survival, inhibit apoptosis, and evade the host immune response (Moore and Chang, 1998; Wen and Damania, 2010).”
BackgroundBoulanger, M. J., Chow, D., Brevnova, E. E., Martick, M. M., Sandford, G. R., Nicholas, J., & García, K. C. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.10.070 · Cited by 72 · cited 2×
“…surgical resection of the spleen, cytotoxic chemotherapy (either single agents or combinations), ganciclovir, glucocorticoids, and rituximab (Boulanger et al., 2004; Waterston and Bower, 2004; Dispenzieri and Gertz, 2005; Neuville et al., 2005; Bower et al., 2007; Mylona et al., 2008;…”
BackgroundNaresh, K. N., Rice, A. J., & Bower, M. (2008) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318160ed97 · Cited by 71 · cited 1×
“Areas of KS spindle cell proliferation in affected nodes are also not uncommon (Naresh et al., 2008).”
BackgroundHIV-associated multicentric Castleman disease
Oksenhendler, É. (2008) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328319bca9 · Cited by 70 · cited 1×
“Common laboratory abnormalities include anemia, thrombocytopenia, hypoalbuminemia, hyponatremia, and elevated inflammatory markers such as C-reactive protein (CRP; Oksenhendler et al., 2000; Oksenhendler, 2009).”
Meads, M. B., & Medveczky, P. G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407382200 · Cited by 67 · cited 3×
“REVIEW ARTICLE published: 02 March 2012 doi: 10.3389/fmicb.2012.00073 Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV–MCD) and the KSHV inflammatory cytokine syndrome”
BackgroundInfluentialStone, S. F., Price, P., Brochier, J., & French, M. A. (2001) · The Journal of Infectious Diseases · doi:10.1086/323599 · Cited by 65 · cited 1×
“Notably, some investigators report elevated hIL-6 levels in IRIS patients without KS, though KSHV and viral cytokines have not, to our knowledge, been assessed in relation to systemic symptoms (Stone et al., 2001).”
BackgroundIntracellular Signaling Mechanisms and Activities of Human Herpesvirus 8 Interleukin-6
Chen, D., Sandford, G. R., & Nicholas, J. (2008) · Journal of Virology · doi:10.1128/jvi.01517-08 · Cited by 64 · cited 1×
“In addition, there is in vitro evidence of vIL-6 autocrine action in lytically infected cells, though the function and significance of this activity is as yet uncertain (Chen et al., 2009a,b).”
BackgroundCytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease
Bower, M., Veraitch, O. K., Szydlo, R., Charles, P., Kelleher, P., Gazzard, B., Nelson, M. R., & Stebbing, J. (2009) · Blood · doi:10.1182/blood-2008-12-197053 · Cited by 55
State-of-the-Art Review: Kaposi's Sarcoma-Associated Herpesvirus-Encoded Interleukin-6
Aoki, Y., Jones, K. D., & Tosato, G. (2000) · Stem Cells and Development · doi:10.1089/152581600319351 · Cited by 52 · cited 2×
“Their sequence homology is approximately 25% (Moore et al., 1996; Neipel et al., 1997). vIL-6 has a signaling potency 100- to 1000-fold lower that that seen with hIL-6 in in vitro models (Aoki et al., 2000).”
Hu, F., & Nicholas, J. (2006) · Journal of Virology · doi:10.1128/jvi.00767-06 · Cited by 45 · cited 1×
“…to signal by forming a tetrameric complex with the IL-6 receptor superfamily gp130 component, which is widely expressed in human tissues, without requiring binding to the classical gp80 IL-6 receptor (Heinrich et al., 1998; Boulanger et al., 2004; Meads and Medveczky, 2004; Hu and Nicholas, 2006).”
BackgroundDavis, D. A., Singer, K. E., Reynolds, I. P., Haque, M., & Yarchoan, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0939 · Cited by 42 · cited 2×
“Our group has explored selective targeting of KSHV–MCD plasmablasts based on their expression of KSHV lytic genes that phosphorylate certain drugs (Davis et al., 2007).”
BackgroundSelf-citationDeterminants of Secretion and Intracellular Localization of Human Herpesvirus 8 Interleukin-6
Chen, D., Choi, Y. B., Sandford, G. R., & Nicholas, J. (2009) · Journal of Virology · doi:10.1128/jvi.02625-08 · Cited by 34 · cited 2×
“REVIEW ARTICLE published: 02 March 2012 doi: 10.3389/fmicb.2012.00073 Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV–MCD) and the KSHV inflammatory cytokine syndrome”
BackgroundInfluentialMicroRNAs of Kaposi's sarcoma-associated herpes virus
Ganem, D., & Ziegelbauer, J. M. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.10.006 · Cited by 23 · cited 1×
“KSHV also encodes at least 12 small non-coding microRNAs (miRNAs), whose functions are still to be comprehensively determined (Ganem and Ziegelbauer, 2008; Umbach and Cullen, 2010).”
BackgroundCD20 expression in the HHV‐8‐infected lymphoid cells in multicentric Castleman disease
Naresh, K. N., Trivedi, P. S., Horncastle, D. E., & Bower, M. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03344.x · Cited by 21 · cited 3×
“KSHV can establish latency in various cell types including endothelial cells and B-lymphocytes (Monini et al., 1999; Wu et al., 2006; Della Bella et al., 2008).”
BackgroundPolizzotto, M. N., Uldrick, T. S., Wang, V., Aleman, K. O., Wyvill, K. M., Marshall, V. A., Pittaluga, S., O’Mahony, D., Whitby, D., Tosato, G., et al. (2011) · Blood · doi:10.1182/blood.v118.21.1573.1573 · Cited by 1 · cited 2×
“This lytic activation, and particularly the production of vIL-6, is thought to underlie its pathogenesis (Oksenhendler et al., 2000; Aoki et al., 2001a; Polizzotto et al., 2011).”
BackgroundSelf-citation
Cited by
Kaposi sarcoma herpesvirus-associated cancers and related diseases
Goncalves, P. H., Ziegelbauer, J., Uldrick, T. S., & Yarchoan, R. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000330 · Cited by 174
Self-citationKSHV LANA—The Master Regulator of KSHV Latency
Uppal, T., Banerjee, S., Sun, Z., Verma, S., & Robertson, E. (2014) · Viruses · doi:10.3390/v6124961 · Cited by 165
Bhutani, M., Polizzotto, M. N., Uldrick, T. S., & Yarchoan, R. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.12.027 · Cited by 155
Self-citation
Metadata
- Authors
- Polizzotto, M. N., Uldrick, T. S., Hu, D., & Yarchoan, R.
- Venue
- Frontiers in Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2012
- Volume
- 3
- Pages
- 1572-1572
- ISSN
- 1664-302X (ISSN-L)
- OpenAlex
- W2069520743
- Cited by
- 196
- References
- 61
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.